Worldwide remdesivir sales forecast 2020-2026

Published by
Matej Mikulic,
Oct 30, 2020
Due to the approval as a COVID-19 treatment, until the end of next year, worldwide sales of Gilead Science's antiviral drug Veklury (remdesivir) is expected to increase to over three billion U.S. dollars. This statistic shows the sales forecast of remdesivir - trademarked as Veklury - worldwide from 2020 to 2026.

Sales forecast of Veklury (remdesivir) worldwide from 2020 to 2026 (in million U.S. dollars)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

July 2020

Region

Worldwide

Survey time period

as of October 2020

Supplementary notes

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Coronavirus: the pharma and medtech response "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic

6

Treatments and vaccines

8

Focus: BioNTech and Moderna

7

Opinions on COVID-19 vaccines

6

Business impact

4

Medtech - before the pandemic

5

Ventilators and testing

7

Further related statistics

20

Further Content: You might find this interesting as well

Statistics

Topics

Coronavirus (COVID-19) vaccines and treatmentsCoronavirus disease (COVID-19) pandemicCoronavirus (COVID-19) in ItalyCoronavirus: impact on the global economyCoronavirus (COVID-19): impact on tech sector
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.